| Year | Strat | MCFTR | Δ |
|---|---|---|---|
| 2026 | +4.1% | -1.2% | +5.3% |
| 2025 | +0.6% | +2.9% | -2.3% |
| 2024 | -1.7% | +1.6% | -3.4% |
| 2023 | +72.7% | +53.8% | +18.8% |
| 2022 | -24.4% | -37.3% | +12.8% |
| 2021 | +38.4% | +21.8% | +16.6% |
| 2020 | +35.7% | +14.8% | +20.9% |
| 2019 | +41.7% | +38.5% | +3.2% |
| 2018 | -1.2% | +19.1% | -20.2% |
| 2017 | +20.2% | -0.2% | +20.3% |
| 2016 | +91.7% | +34.8% | +56.9% |
RU non-financials growing at a reasonable price (positive value-creation), profitable, liquid (cap >= 20bn RUB), with a real 3-year revenue base. Ranked by 3y revenue CAGR plus an acceleration reward (latest-year vs prior-year growth), dropping sharply decelerating names. Top 10 equal weight, monthly. Total return.
| Period | Strategy | MCFTR | vs index |
|---|---|---|---|
| Day | +0.0% | +0.8% | -0.7% |
| Week | -0.0% | +1.6% | -1.7% |
| Month | +5.1% | +11.3% | -6.2% |
| YTD | +3.7% | +4.1% | -0.4% |
| Holding | Weight | Day | growth+accel |
|---|---|---|---|
| DATA revenue 3y CAGR +51%/yr; growth accelerating (latest yr +97% vs prior -4%); value-creation/FVC +131394%. | 10.0% | +0.1% | 96% |
| UGLD revenue 3y CAGR +41%/yr; growth accelerating (latest yr +73% vs prior +18%); value-creation/FVC +133%. | 10.0% | +0.0% | 74% |
| PRMD revenue 3y CAGR +52%/yr; growth accelerating (latest yr +74% vs prior +69%); value-creation/FVC +41%. | 10.0% | +0.1% | 55% |
| SELG revenue 3y CAGR +32%/yr; growth accelerating (latest yr +51% vs prior +20%); value-creation/FVC +157%. | 10.0% | +0.1% | 51% |
| DOMRF revenue 3y CAGR +41%/yr; growth accelerating (latest yr +45% vs prior +33%); value-creation/FVC +47%. | 10.0% | +0.0% | 48% |
| POSI revenue 3y CAGR +31%/yr; growth accelerating (latest yr +30% vs prior +14%); value-creation/FVC +486%. | 10.0% | +0.0% | 41% |
| CNRU revenue 3y CAGR +20%/yr; growth accelerating (latest yr +23% vs prior +5%); value-creation/FVC +51%. | 10.0% | -0.1% | 30% |
| YDEX revenue 3y CAGR +34%/yr; growth slowing (latest yr +24% vs prior +35%); value-creation/FVC +50%. | 10.0% | -0.0% | 28% |
| GEMC revenue 3y CAGR +16%/yr; growth accelerating (latest yr +22% vs prior +3%); value-creation/FVC +3%. | 10.0% | +0.2% | 28% |
| MDMG revenue 3y CAGR +22%/yr; growth accelerating (latest yr +28% vs prior +20%); value-creation/FVC +10%. | 10.0% | +0.0% | 27% |
| Rebalance | Signal | Holding | Price (RUB) | Weight | Result |
|---|---|---|---|---|---|
| 13 Oct 2026 | Buy | GEMC United Medical Group revenue 3y CAGR +16%/yr; growth accelerating (latest yr +22% vs prior +3%); value-creation/FVC +3%. | 621.20 | 10.0% | — |
| Sell | OZPH Ozon Pharm dropped out of the top ranking (entry score was 22%) | 46.14 | — | +11.2% | |
| 5 Oct 2026 | Buy | DATA ArenaData revenue 3y CAGR +51%/yr; growth accelerating (latest yr +97% vs prior -4%); value-creation/FVC +133777%. | 88.78 | 10.0% | — |
| Sell | VKCO VK company dropped out of the top ranking (entry score was 20%) | 116.50 | — | +3.4% | |
| 29 Sep 2026 | Buy | VKCO VK company revenue 3y CAGR +14%/yr; growth accelerating (latest yr +12% vs prior +3%); value-creation/FVC +106%. | 112.70 | 10.0% | — |
| Sell | DATA ArenaData dropped out of the top ranking (entry score was 96%) | 84.42 | — | -3.7% | |
| 4 Sep 2026 | Buy | DATA ArenaData revenue 3y CAGR +51%/yr; growth accelerating (latest yr +97% vs prior -4%); value-creation/FVC +133383%. | 87.62 | 10.0% | — |
| Sell | VKCO VK company dropped out of the top ranking (entry score was 20%) | 121.20 | — | +0.7% | |
| 28 Aug 2026 | Buy | SELG Seligdar revenue 3y CAGR +32%/yr; growth accelerating (latest yr +51% vs prior +20%); value-creation/FVC +167%. | 36.66 | 10.0% | — |
| Buy | MDMG MD Medical revenue 3y CAGR +22%/yr; growth accelerating (latest yr +28% vs prior +20%); value-creation/FVC +10%. | 1 301 | 10.0% | — | |
| Sell | MTSS MTS dropped out of the top ranking (entry score was 16%) | 180.10 | — | +0.7% | |
| Sell | RTKM Rostelecom dropped out of the top ranking (entry score was 13%) | 39.24 | — | -0.3% | |
| 27 Aug 2026 | Buy | RTKM Rostelecom revenue 3y CAGR +12%/yr; growth accelerating (latest yr +12% vs prior +10%); value-creation/FVC +113%. | 39.36 | 10.0% | — |
| Sell | SOFL Softline dropped out of the top ranking (entry score was 23%) | 54.26 | — | +2.7% | |
| 24 Aug 2026 | Buy | PRMD Promomed revenue 3y CAGR +41%/yr; growth accelerating (latest yr +75% vs prior +35%); value-creation/FVC +51%. | 369.05 | 10.0% | — |
| Buy | VKCO VK company revenue 3y CAGR +14%/yr; growth accelerating (latest yr +12% vs prior +3%); value-creation/FVC +94%. | 120.30 | 10.0% | — | |
| Buy | OZPH Ozon Pharm revenue 3y CAGR +19%/yr; growth slowing (latest yr +24% vs prior +30%); value-creation/FVC +46%. | 41.49 | 10.0% | — | |
| Buy | MTSS MTS revenue 3y CAGR +14%/yr; growth slowing (latest yr +15% vs prior +16%); value-creation/FVC +69%. | 178.85 | 10.0% | — | |
| Sell | SELG Seligdar dropped out of the top ranking (entry score was 62%) | 38.56 | — | -4.9% | |
| Sell | LENT Lenta dropped out of the top ranking (entry score was 35%) | 1 916 | — | -0.2% | |
| Sell | BELU Beluga dropped out of the top ranking (entry score was 15%) | 247.60 | — | -3.8% | |
| Sell | RTKM Rostelecom dropped out of the top ranking (entry score was 13%) | 39.85 | — | -18.6% | |
| 14 Aug 2026 | Buy | BELU Beluga revenue 3y CAGR +13%/yr; growth accelerating (latest yr +10% vs prior +7%); value-creation/FVC +25%. | 257.40 | 10.0% | — |
| Sell | OZON dropped out of the top ranking (entry score was 85%) | 2 926 | — | -25.3% | |
| 4 Aug 2026 | Buy | LENT Lenta revenue 3y CAGR +33%/yr; growth accelerating (latest yr +26% vs prior +22%); value-creation/FVC +17%. | 1 918 | 10.0% | — |
| Sell | BELU Beluga dropped out of the top ranking (entry score was 15%) | 283.20 | — | +7.8% | |
| 28 Jul 2026 | Buy | SOFL Softline revenue 3y CAGR +19%/yr; growth accelerating (latest yr +18% vs prior +11%); value-creation/FVC +55%. | 52.84 | 10.0% | — |
| Buy | BELU Beluga revenue 3y CAGR +13%/yr; growth accelerating (latest yr +10% vs prior +7%); value-creation/FVC +28%. | 262.80 | 10.0% | — | |
| Sell | GCHE Cherkizovo dropped out of the top ranking (entry score was 16%) | 3 079 | — | -1.9% | |
| Sell | MDMG MD Medical dropped out of the top ranking (entry score was 8%) | 1 275 | — | +21.1% | |
| 18 Jul 2026 | Buy | MDMG MD Medical revenue 3y CAGR +13%/yr; growth slowing (latest yr +11% vs prior +20%); value-creation/FVC +15%. | 1 053 | 10.0% | — |
| Sell | BELU Beluga dropped out of the top ranking (entry score was 15%) | 207.00 | — | -21.2% | |
| 24 Jun 2026 | Buy | BELU Beluga revenue 3y CAGR +13%/yr; growth accelerating (latest yr +10% vs prior +7%); value-creation/FVC +25%. | 262.60 | 10.0% | — |
| Sell | SOFL Softline dropped out of the top ranking (entry score was 23%) | 44.52 | — | -15.6% |
Prices are the frozen close on the signal date — the price at which the live model portfolio starts (buy) or stops (sell) holding the position. Sell result is the price change from the position's own buy signal, dividends not included.